Product description from the company website...
Curidium has developed a research platform that combines and integrates target discovery research with clinical data, to determine the underlying disease mechanisms or "molecular signatures" of disease. Known as Homomatrix® , the technology has adopted principles of genetics, molecular pharmacology and epidemiology to analyse biological data from disease and control patients.
Schematic representation of the application of Homomatrix:
(IP: Intellectual Property to Curidium / ID: Identification)
Curidium applies Homomatrix® to either gene (mRNA) expression data or protein activity measurements derived from any gene, protein or pharmacologically tractable target. It is a systematic process, allowing a gene or protein to be analysed and characterised as contributing to a potential disease mechanism.
On a genome-wide scale (e.g. using gene-expression microarrays), Homomatrix® is applied to identify underlying disease mechanisms, including signalling pathways and potentially novel gene-gene associations. The combined findings, covering the whole or a large part of the human genome, segregate the patient population studied into subgroups, each with a distinct molecular signature. Although the method has strong bioinformatics and biostatistics components, its uniqueness stems from a collection of proprietary pattern recognition tools and specific sequences of mathematical algorithms and statistical methods used to analyse human biological data.
Complemented by extensive know-how developed within Curidium, Homomatrix® is operated and managed in house, in support of target discovery, diagnostic and clinical development for internal programmes and planned customised collaborations with corporate partners.
Link to Company Website